1. Introduction 1.1 Market Definition 2. Research Methodology 3. Executive Summary 4. Key Inferences 5. Market Overview 5.1 Current Market Scenario 5.2 Porter's Five Forces Analysis 5.2.1 Bargaining Power of Suppliers 5.2.2 Bargaining Power of Consumers 5.2.3 Threat of New Entrants 5.2.4 Threat of Substitute Products and Services 5.2.5 Competitive Rivalry within the Industry 6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC) 6.1 Drivers 6.1.1 Rising Prevalence of Diabetes 6.1.2 Better Adoption than Other Therapies 6.1.3 Government Initiatives 6.2 Restraints 6.2.1 High Cost of Diabetes Medications 6.2.2 Regulatory Framework 6.2.3 Adverse Reaction of Medications 6.3 Opportunities 6.4 Key Challenges 7. Market Segmentation 7.1 By Drugs 7.1.1 Injectables 7.1.1.1 Insulin 7.1.1.1.1 Rapid-acting Insulin 7.1.1.1.2 Intermediate-acting Insulin 7.1.1.1.3 Long-acting Insulin 7.1.2 Oral 7.1.2.1 Oral Diabetic Medication Drugs 7.1.2.1.1 Sulfonylurea 7.1.2.1.2 Meglitinide 7.1.2.1.3 Glucagon-like Peptide-1 Receptor Agonist 7.1.2.1.4 Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors 7.1.2.1.5 Biguanide 7.1.2.1.6 Thiazolidinediones 7.1.2.1.7 Others 7.2 By Geography 7.2.1 North America 7.2.1.1 United States 7.2.1.2 Canada 7.2.1.3 Mexico 7.2.2 Europe 7.2.2.1 France 7.2.2.2 Germany 7.2.2.3 United Kingdom 7.2.2.4 Italy 7.2.2.5 Spain 7.2.2.6 Rest of Europe 7.2.3 Asia-Pacific 7.2.3.1 China 7.2.3.2 Japan 7.2.3.3 India 7.2.3.4 Australia & New Zealand 7.2.3.5 South Korea 7.2.3.6 Rest of Asia-Pacific 7.2.4 Middle East & Africa 7.2.4.1 GCC 7.2.4.2 South Africa 7.2.4.3 Rest of the Middle East & Africa 7.2.5 South America 7.2.5.1 Brazil 7.2.5.2 Argentina 7.2.5.3 Rest of South America 8. Competitive Landscape 8.1 Mergers & Acquisition Analysis 8.2 Agreements, Collaborations, and Partnerships 8.3 New Products Launches 9. Key Players 9.1 Abbott Laboratories 9.2 AstraZeneca 9.3 Bayer AG 9.4 Eli Lilly and Company 9.5 GlaxoSmithKline PLC 9.6 Johnson & Johnson 9.7 Merck & Co. 9.8 Novo Nordisk *List not Exhaustive 10. Future of the Market 11. Disclaimer

Abbott Laboratories, Johnson & Johnson, Merck & Co., Novo Nordisk, Eli Lilly and Company, AstraZeneca, GlaxoSmithKline PLC, Bayer AG